Lymphatic Malformations
11
2
2
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
9.1%
1 terminated out of 11 trials
87.5%
+1.0% vs benchmark
9%
1 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (11)
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Bleomycin Intralesional Injections of Cystic Hygromas
A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome
Bleomycin as an Effective and Curative Adjunct Therapy for Lymphangioma
Sildenafil for the Treatment of Lymphatic Malformations
OK432 (Picibanil) in the Treatment of Lymphatic Malformations
Airway Vascular Lesions
Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations
Selenium in the Treatment of Complicated Lymphatic Malformations
Diagnosis of Hemangiomas and Vascular Malformations